KalVista Pharmaceuticals, based in Cambridge, Massachusetts, specializes in small molecule protease inhibitors for unmet medical needs, focusing on hereditary angioedema treatments like sebetralstat and Factor XIIa inhibitors. The company went public in April 2015 and employs 150 staff.
KalVista Pharmaceuticals (KALV) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, KalVista Pharmaceuticals's actual EPS was -$0.99, missing the estimate of -$0.80 per share, resulting in a -24.26% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
